Topiramate-induced psychotic exacerbation: case report and review of literature

References

• Sabers AS, Gram L. Drug treatment of epilepsy in the 1990s: achievements and new developments. Drugs 1996; 52: 483–93
   PubMed Web of Science ®Google Scholar
• Privitera MD. Topiramate: a new antiepileptic drug. Ann Pharmacother 1997; 31: 1164–73
   PubMed Web of Science ®Google Scholar
• Shank RP, Gardocki JF, Streater AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000; 41(Suppl 1)S3–9
   PubMed Web of Science ®Google Scholar
• Marcotte D. Use of topiramate, a new anti-epileptic, as a mood stabilizer. J Affect Disord 1998; 50: 245–51
   PubMed Web of Science ®Google Scholar
• Deutsch SI, Rosse RB, Billingslea EN, Bellack AS, Mastropaolo J. Topiramate antagonizes MK-801 in an animal model of schizophrenia. Eur J Pharmocol 2002; 449: 121–5
   PubMed Web of Science ®Google Scholar
• Deutsch SI, Schwartz BL, Rosse RB, Mastropaolo J, Marvel CL, Drapalski AL. Adjuvant topiramate administration: A pharmacologic strategy for adressing NMDA receptor hypofunction in schizophrenia. Clin Neuropharmacol 2003; 26(4)199–206
   PubMed Web of Science ®Google Scholar
• Chengappa KNR, Gershon S, Levine J. The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Disord 2001; 3: 215–22
   PubMed Web of Science ®Google Scholar
• McElroy SL, Suppes T, Keck PE, et al. Open–label adjunctive topiramate in the treatment of bipolar disorder. Biol Psychiatry 2000; 47: 1025–33
   PubMed Web of Science ®Google Scholar
• Andrade C. Confusion and dysphoria with low-dose topiramate in a patient with bipolar disorder. Bipolar Disord. 2001; 3(4)211–12
   PubMed Web of Science ®Google Scholar
• Bertant JL. Topiramate in PTSD: Preliminary clinical observations. J Clin Psychiatry 2001; 62(Suppl 17)60–3
   Google Scholar
• Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: A clinical case series. J Clin Psychiatry 2000; 61: 368–72
   PubMed Web of Science ®Google Scholar
• Mathew NT, Kailasam J, Meadors L. Prophylaxis of migraine, transformed migraine and cluster headache with topiramate. Headache 2002; 42: 796–803
   PubMed Web of Science ®Google Scholar
• Schuler-Springorum M, Hebebrand J, Wehmeier PM, Remschmidt H. Is topiramate effective for weight loss in neuroleptic-induced obesity? 2 case reports. Z Kinder Jugendpsychiatr Psychother 2002; 30(1)51–8
   PubMed Web of Science ®Google Scholar
• Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss [letter]. Can J Psychiatry 2000; 45: 198
   PubMed Web of Science ®Google Scholar
• Khan A, Faught E, Gillian F, Kuzniecki R. Acute psychotic symptoms induced by topiramate. Seizure 1999; 84: 235–7
   Google Scholar
• Stella F, Caetano D, Cendes F, Guerreiro CA. Acute psychotic disorders induced by topiramate: report of two cases. Arq Neuropsiquiatr 2002; 60(2-A)285–7
   PubMed Web of Science ®Google Scholar
• Verhoeven WM, Boermans JA, van der Heijden FM, Tuinier S. Psychosis following treatment with topiramate. Ned Tijdschr Geneeskd 2002; 146(44)2093–5
   PubMedGoogle Scholar
• Matthews SC, Miller PB. Auditory hallucinations associated with topiramate. J Clin Psychiatry 2001; 62(8)653
   PubMed Web of Science ®Google Scholar
• Garcia Cabeza GI, Gutierrez Rodriguez M, Epifanio Gutierrez MM. Psychosis with topiramate. Actas Esp Psiquiatr 2000; 28(3)202–4
   PubMed Web of Science ®Google Scholar
• Biton V, Montouris GD, et al. A randomized placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group. Neurology 1999; 52: 1330–7
   PubMed Web of Science ®Google Scholar
• Tassinari CA, Michelucci R, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996; 37: 763–8
   PubMed Web of Science ®Google Scholar
• Hermann BP, Seidenberg M, Bell B. Psychiatric comorbidity in chronic epilepsy: identification consequences, and treatment of major depression. Epilepsia 2000; 41: S31–41
   Google Scholar
• Kanner AM, Palac S. Depression in epilepsy: a common but often unrecognized comorbid malady. Epilepsy Behav 2000; 1: 37–51
   PubMed Web of Science ®Google Scholar
• Sachdev P. Schizophrenia-like psychosis and epilepsy: the status of the association. Am J Psychiatry 1998; 155: 325–36
   PubMed Web of Science ®Google Scholar
• Trimble MR. The psychosis of epilepsy and their treatment. Clinical Neuropharmacology 1985; 8: 211–20
   PubMed Web of Science ®Google Scholar
• Landolt H. Some clinical and electroencephalographical correlations in epileptic psychosis (twilight studies). Electroencephalogr Clin Neurophysiol 1953; 5: 121
   Google Scholar
• Wolf P. Acute behevioral symptomatology at disappearance of epileptiform EEG abnormality: paradoxical or forced normalisation. Advances in neurology. Raven Press, New York 1991; 55: 127–42
   Google Scholar
• Wiegartz P, Seidenberg M, Woodard A, et al. Co-morbid psychiatric disorder in chronic epilepsy: recognition and etiology of depression. Neurology 1999; 53(Suppl 2)S3–8
   PubMedGoogle Scholar
• Trimble MR, Rusch N, Betts T, Crawford PM. Psychiatric symptoms after therapy with new antiepileptic drugs: Psychopathological and seizure related variables. Seizure 2000; 9: 249–54
   PubMed Web of Science ®Google Scholar
• Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000; 41: 1167–78
   PubMed Web of Science ®Google Scholar
• Reife R, Pledger G, Wu SC. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000; 41(Suppl 1)66–71
   PubMedGoogle Scholar
• Drapalski AL, Rosse RB, Peebles RR, Schwartz BL, Marvel CL, Deutsch SI. Topiramate improve deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. Clin Neuropharmacol 2001; 24: 290–4
   PubMed Web of Science ®Google Scholar
• Hofer A, Fleischhacker WW, Hummer M. Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenic patient [letter]. J Clin Psychiatry 2003; 64(10)1267–8
   PubMed Web of Science ®Google Scholar
• Dursun SM, Deakin JFW. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment resistant schizophrenia: a naturalistic case series outcome study. J Psychopharmacol 2001; 15: 297–301
   PubMed Web of Science ®Google Scholar
• Sherman AD, Davidson AT, Baruah S, Hegwood TS, Waziri R. Evidence of glutamatergic deficiency in schizophrenia. Neurosci Lett 1991; 121(1–2)77–80
   PubMed Web of Science ®Google Scholar
• Kober D, Gabbard GO. Topiramate-induced psychosis. Am J Psychiatry 2005; 162: 1542
   PubMed Web of Science ®Google Scholar
• Millson RC, Owen JA, Lorberg GW, et al. Topiramate for refractory schizophrenia [letter]. Am J Psychiatry 2002; 159: 675
   PubMed Web of Science ®Google Scholar
• Kanner AM, Wuu J, Faught E, et al. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 2003; 4: 548–52
   PubMed Web of Science ®Google Scholar
• Mula M, Trimble MR. The importance of being seizure free: topiramate and psychopathology in epilepsy. Epilepsy Behav 2003; 4(4)430–4
   PubMed Web of Science ®Google Scholar
• Mula M, Trimble MR, Lhatoo SD, Sander JW. Topiramate and psychiatric adverse events in patients with epilepsy Epilepsia 2003; 44(5)659–63
   Google Scholar
• Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin Neuropharmacol 2001; 24: 43–9
   PubMed Web of Science ®Google Scholar